May 3, 2018 / 1:59 PM / 5 months ago

BRIEF-Teva CEO To Reuters: Migraine drug to be priced at about $10,000 a year

May 3 (Reuters) - Teva Pharmaceutical Industries Ltd :

* TEVA PHARM CEO TO REUTERS: "CLOSE RACE" WITH ELI LILLY FOR SECOND MIGRAINE DRUG LAUNCH

* TEVA PHARM CEO TO REUTERS: MIGRAINE DRUG TO BE PRICED AT ABOUT $10,000 A YEAR, SIMILAR TO COMPETITORS

* TEVA CEO TO REUTERS: WE ARE SEEING SOME STABILIZATION IN U.S. GENERIC DRUG PRICES

* TEVA CEO TO REUTERS: WORKING WITH CUSTOMERS TO ENSURE PATIENTS NOT AFFECTED AS IT PHASES OUT SOME GENERIC DRUG PRODUCTS

* TEVA CEO TO REUTERS: U.S. BIOSIMILAR MARKET IN EARLY STAGES SO TEVA WILL BE ABLE TO CATCH UP Further company coverage: (Reporting by Steven Scheer and Tova Cohen)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below